Researchers investigated non-melanoma skin cancer prevalence among sexual orientation identities by race/ethnicity and gender.

Researchers reported on patient acceptance of an e-consent tool for asynchronous delivery of study information and for receiving consent from patients.

Median progression-free survival was 22 months, overall survival was 152 months among patients with newly diagnosed MM.

Medical professionals who use social media to educate the public on health-related topics have grown in prominence.

Researchers assessed variations in patterns of care and time to initial treatment for women diagnosed with breast, cervical, or ovarian cancer in various countries.

These findings indicate serial ctDNA monitoring could identify patients with muscle-invasive bladder cancer who benefit from adjuvant atezolizumab, while sparing patients who are persistently negative ...

PRRT retreatment may be well tolerated and confer a survival benefit in patients with well-differentiated, metastatic neuroendocrine tumors, a study suggests.

Thrombotic risk with PICCs matched that of totally implantable venous access devices, showing comparable long-term safety.

POTOMAC supports 1 year of durvalumab with BCG induction and maintenance therapy as a potential new treatment in BCG-naïve, high-risk NMIBC,” said Maria De Santis, MD.